Key Market Indicators
Sales of antirheumatic medicine in Hungary are forecast to drop 6% annually over the next five years, reaching $12.4 million in 2026. Since 2008, the Hungarian market has decreased by an average of 1.8% each year. In 2021, the country ranked 19th, with Latvia in the top spot at $18.2 million. Germany, Spain and Canada took the 2nd, 3rd and 4th spots, respectively.
